Abstract
Background Healthcare workers are at a higher risk of getting infected with SARS-CoV-2 than the general population. However, detailed knowledge about medical students and exposure to SARS-CoV-2 is lacking. Thus, we measured the prevalence of SARS-CoV-2 antibodies in a cohort of Danish medical students.
Methods We invited all medical students at the University of Copenhagen (UCPH) to participate. A venous blood sample was drawn along with completing a self-report questionnaire. Blood samples were analyzed for total antibodies to SARS-CoV-2 and related to symptomatology, social behaviour, and work-life. Seropositive samples were screened for IgM, IgG, and IgA antibodies.
Results Between October 19th and 26th 1,120 students participated in questionnaire, of these 1,096 were included in the study. Of all included 379 (34.58%) of the participants were seropositive. The risk of seropositivity was significantly increased for participants attending two parties at UCPH, on February the 29th and March 6th 2020 (OR 5.96 (95% CI 4.34-8.24, p<0.001). Further, 461 students (42.06%) worked with COVID-19 patients, which was significantly associated with risk of seropositivity (OR 1.38, 95% CI 1.03-1.85, p=0.033). The symptom most substantially associated with seropositivity was loss of smell and/or taste (n=183 of all, 31.35%) with an OR of 24.48 (95% CI 15.49-40.60, p<0.001).
Conclusion Medical students have the highest reported seropositivity in the Danish healthcare system. The risk of SARS-CoV-2 transmission amongst the students appear to be partly related to working with COVID-19 infected patients, but to a greater extent, their social behaviour.
Mainpoints Medical students have the highest reported seropositivity in the Danish healthcare system. The risk of SARS-CoV-2 transmission amongst the students appear to be partly related to working with COVID-19 infected patients, but to a greater extent, their social behaviour.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the Carlsberg Foundation [CF20-476 0045]; The Novo Nordisk Foundation [NFF205A0063505 and NNF20SA0064201] and the Union of Danish medical students (FADL). The funders did not influence study design, conduct or reporting.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study complied with the Declaration of Helsinki II and was approved by the regional ethics committee of the Capital Region (H-20055767) and by the Danish Data Protection Authorities (P-2020-92). Following the guidelines for the provision of oral and written information, all patients gave written informed consent to participate in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No data are available
